Emerging treatments
Pomalidomide
Pomalidomide, an angiogenesis inhibitor and thalidomide analog, was shown to significantly reduce epistaxis occurrence in patients with hereditary hemorrhagic telangiectasia in one randomized control trial (n=144); there were no unexpected safety signals.[68]
Use of this content is subject to our disclaimer